125 related articles for article (PubMed ID: 10806842)
1. Clinical implication of serum sIL-2R levels in ovarian cancer.
Wang S; Cai G; Lu Y
J Tongji Med Univ; 1998; 18(2):126-8. PubMed ID: 10806842
[TBL] [Abstract][Full Text] [Related]
2. Serum soluble interleukin-2 receptor assay in epithelial ovarian cancer.
Ferdeghini M; Gadducci A; Prontera C; Malagnino G; Fanucchi A; Annicchiarico C; Facchini V; Bianchi R
Tumour Biol; 1993; 14(5):303-9. PubMed ID: 8235309
[TBL] [Abstract][Full Text] [Related]
3. Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer.
Gadducci A; Ferdeghini M; Malagnino G; Prontera C; Fanucchi A; Annicchiarico C; Bianchi R; Fioretti P; Facchini V
Gynecol Oncol; 1994 Mar; 52(3):386-91. PubMed ID: 8157196
[TBL] [Abstract][Full Text] [Related]
4. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer.
Hurteau JA; Woolas RP; Jacobs IJ; Oram DC; Kurman CC; Rubin LA; Nelson DL; Berchuck A; Bast RC; Mills GB
Cancer; 1995 Nov; 76(9):1615-20. PubMed ID: 8635066
[TBL] [Abstract][Full Text] [Related]
5. [Soluble interleukin-2 receptor level in the sera and ascitic fluids in patients with ovarian cancer].
Pu FR; Cheng SW; Zhu D
Zhonghua Fu Chan Ke Za Zhi; 1994 Aug; 29(8):478-80, 511. PubMed ID: 7835120
[TBL] [Abstract][Full Text] [Related]
6. Prognostic relevance of soluble interleukin-2 receptors in patients with ovarian tumors.
Gebauer G; Rieger M; Jäger W; Lang N
Anticancer Res; 1999; 19(4A):2509-11. PubMed ID: 10470184
[TBL] [Abstract][Full Text] [Related]
7. Significance of serum and peritoneal fluid lactate dehydrogenase levels in ovarian cancer.
Boran N; Kayikçioğlu F; Yalvaç S; Tulunay G; Ekinci U; Köse MF
Gynecol Obstet Invest; 2000; 49(4):272-4. PubMed ID: 10828712
[TBL] [Abstract][Full Text] [Related]
8. High serum and ascitic soluble interleukin-2 receptor alpha levels in advanced epithelial ovarian cancer.
Barton DP; Blanchard DK; Michelini-Norris B; Nicosia SV; Cavanagh D; Djeu JY
Blood; 1993 Jan; 81(2):424-9. PubMed ID: 8422462
[TBL] [Abstract][Full Text] [Related]
9. The clinical significance of serum soluble interleukin 2 receptor (sIL-2R) concentration in lung cancer.
Naumnik W; Chyczewska E
Folia Histochem Cytobiol; 2001; 39 Suppl 2():185-6. PubMed ID: 11820599
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
[TBL] [Abstract][Full Text] [Related]
11. Soluble interleukin-2 receptors (sIL-2R) in ovarian cancer patients: changes in sIL-2R after surgery as a prognostic factor?
Gebauer G; Rieger M; Jäger W; Lang N
Int J Biol Markers; 1998; 13(1):45-7. PubMed ID: 9681299
[No Abstract] [Full Text] [Related]
12. [Analysis of serum biomarkers of ovarian epithelial cancers based on 2-DE DIGE and MALDI TOF/TOF].
Zhao Q; Duan W; Wu YM; Qian XH; Deng XH
Zhonghua Zhong Liu Za Zhi; 2008 Oct; 30(10):754-8. PubMed ID: 19173805
[TBL] [Abstract][Full Text] [Related]
13. [Clinical significance of serum soluble interleukin-2 receptor level in patients with non-Hodgkin's lymphoma].
Shimomura Y; Tsurumi H; Sawada M; Yamada T; Hara T; Fukuno K; Goto H; Moriwaki H
Rinsho Ketsueki; 1999 Aug; 40(8):639-45. PubMed ID: 10496038
[TBL] [Abstract][Full Text] [Related]
14. Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma.
Kudoh K; Kikuchi Y; Kita T; Tode T; Takano M; Hirata J; Mano Y; Yamamoto K; Nagata I
Gynecol Obstet Invest; 1999; 47(1):52-7. PubMed ID: 9852392
[TBL] [Abstract][Full Text] [Related]
15. Serum level of a soluble receptor for interleukin-2 as a prognostic factor in patients with gastric cancer.
Saito H; Tsujitani S; Ikeguchi M; Maeta M; Kaibara N
Oncology; 1999 Apr; 56(3):253-8. PubMed ID: 10202282
[TBL] [Abstract][Full Text] [Related]
16. Serum-soluble IL-2 receptor and IL-6 levels in patients with melanoma.
Boyano MD; García-Vázquez MD; Gardeazabal J; García de Galdeano A; Smith-Zubiaga I; Cañavate ML; Raton JA; Bilbao I; Díaz-Pérez JL
Oncology; 1997; 54(5):400-6. PubMed ID: 9260602
[TBL] [Abstract][Full Text] [Related]
17. Soluble Interleukin-2 Receptor: A Potential Marker for Monitoring Disease Activity in IgG4-Related Disease.
Karim AF; Eurelings LEM; Bansie RD; van Hagen PM; van Laar JAM; Dik WA
Mediators Inflamm; 2018; 2018():6103064. PubMed ID: 29686532
[TBL] [Abstract][Full Text] [Related]
18. Myeloid marker S100A8/A9 and lymphocyte marker, soluble interleukin 2 receptor: biomarkers of hidradenitis suppurativa disease activity?
Wieland CW; Vogl T; Ordelman A; Vloedgraven HG; Verwoolde LH; Rensen JM; Roth J; Boer J; Hessels J
Br J Dermatol; 2013 Jun; 168(6):1252-8. PubMed ID: 23320892
[TBL] [Abstract][Full Text] [Related]
19. [The serum levels of soluble interleukin-2 receptor in patients with malignant lymphocytic proliferative disorders].
Xu J; Wang B
Zhonghua Xue Ye Xue Za Zhi; 1998 Feb; 19(2):82-4. PubMed ID: 10921108
[TBL] [Abstract][Full Text] [Related]
20. Soluble interleukin 2 receptor in lung cancer. An indirect marker of tumor activity?
Buccheri G; Marino P; Preatoni A; Ferrigno D; Moroni GA
Chest; 1991 Jun; 99(6):1433-7. PubMed ID: 2036827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]